# Safety and Efficacy of Allogeneic Cells for the Treatment of Intermittent Claudication(IC)

Study · id `cardio:ct-nct01679990` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01679990](<https://clinicaltrials.gov/study/NCT01679990>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT01679990

Browse, organ or system: Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 180 participants.

## Technical summary

Registry record NCT01679990. Randomized; double masking; primary purpose treatment. Start 2012-11-05 (registry gives no type); primary completion 2018-03-29 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 180 participants (enrolled count; ClinicalTrials.gov record NCT01679990, source copy `cardio:ctgov-nct01679990-2019-02-12`, retrieved 2026-10-31)
- Start date: 2012-11-05 (registry gives no type) (ClinicalTrials.gov record NCT01679990, source copy `cardio:ctgov-nct01679990-2019-02-12`, retrieved 2026-10-31)
- Primary completion: 2018-03-29 (actual) (ClinicalTrials.gov record NCT01679990, source copy `cardio:ctgov-nct01679990-2019-02-12`, retrieved 2026-10-31)
- Completion: 2019-02-09 (actual) (ClinicalTrials.gov record NCT01679990, source copy `cardio:ctgov-nct01679990-2019-02-12`, retrieved 2026-10-31)
- Countries: United States; Germany; Israel; South Korea (ClinicalTrials.gov record NCT01679990, source copy `cardio:ctgov-nct01679990-2019-02-12`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01679990-2019-02-12`, retrieved 2026-10-31)

## The registry's words

- Brief title: Safety and Efficacy of Allogeneic Cells for the Treatment of Intermittent Claudication(IC)
- Condition: Intermittent Claudication
- Condition: Peripheral Artery Disease
- Intervention (Biological): PLX-PAD Low dose
- Intervention (Biological): PLX-PAD high doses
- Intervention (Biological): Double Placebo
- Intervention (Biological): high dose +Placebo
- Lead sponsor: Pluristem Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Peripheral artery disease (`cardio:peripheral-artery-disease`)

## Provenance

Content hash: ae88f02286b6bee6df90a43f21fcf02ea9e9c2719bb815e04e79c00df56d910d
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
